This meta-analysis looked at how liposomal bupivacaine, used in transversus abdominis plane blocks, compares to standard bupivacaine for pain control after surgery. The review pooled data from studies involving 1,528 patients who had surgery and received these blocks for postoperative pain relief.
The main finding was that liposomal bupivacaine led to a small reduction in morphine use on the first day after surgery. It also showed slightly lower pain scores on the first three days and a longer time before needing more pain medicine. However, the quality of the evidence was rated as low to very low for these outcomes.
No serious safety problems were reported in the studies, but the review did not provide detailed safety data. The main reason to be careful is that the evidence is not strong, and large-scale trials are needed to confirm these small effects.
The takeaway is that liposomal bupivacaine may offer only minimal improvements in pain and opioid use compared to standard bupivacaine after surgery. Patients should discuss options with their care team.